Dr. Srinivas Chilukuri - Radiation Oncologist at Chennai,Senior Consultan - Radiation Oncology,

Dr. Srinivas Chilukuri

Senior Consultan - Radiation Oncology

Consultation Online Consultation

Biography

Dr. Srinivas Chilukuri is an accomplished Radiation Oncologist and a key opinion leader in radiation oncology. His core area of expertise lies in high-precision radiation therapy, including Particle Beam Therapy.He has 18 yeras of experience. He is credited with initiating South Asia and India’s first clinical programme for particle beam therapy for pediatric cancers, prostate cancers, and thoracic cancers and sarcomas.

Dr. Chilukuri was trained from some of the finest institutions such as Armed Forces Medical College and Tata Memorial Hospital, and had exposure to some of the world’s best institutions, including Miami Cancer Institute and Mayo Clinic. He has been awarded fellowships by the American Society of Oncology and the European medical oncology society for being one of the most promising oncologists.

Areas of Expertise

  • Paediatric Cancers
  • Thoracic Cancers
  • Lymphomas
  • Genito Urinary Cancers
  • Bone and Soft Tissue
  • Proton Beam Therapy

Education & Training

  • Graduation at Armed Forces Medical College, Pune, where he completed his training with a University Top Rank under the supervision of the legendary Dr. Ketayun Dinshaw.

Professional Work

  • Senior Consultant, Radiation Oncology at Apollo Proton Cancer Centre, Chennai.
  • Significantly contributed to establishing RapidArc, IGRT, SRS, and SBRT programmes at YCI.
  • Instrumental in establishing and running Varian School for High Precision Radiotherapy (in collaboration with Varian Medical Systems), which has to date trained more than 220 radiation oncologists and physicists across the Indian subcontinent.
  • Recently joined as Consultant-Medical affairs for Varian Medical Systems. He will be providing medical and scientific guidance, envisioning novel applications of new and existing technologies, and will be representing Varian in regulatory board meetings as well as during interactions with the government.